Eckert & Ziegler SE Annual General Meeting Approves Significantly Higher Dividend

The Annual General Meeting of Eckert & Ziegler SE, held at the company's headquarters in Berlin, approved a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 in the previous year. The proposal by the Executive Board and Supervisory Board was adopted by a large majority, with 55.37% of the company's share capital represented at the meeting.

The meeting, conducted as an in-person event, endorsed the actions of the Executive Board and Supervisory Board for the 2025 fiscal year and approved all agenda items. Detailed voting results and the CEO's presentation are available on the Eckert & Ziegler website.

Eckert & Ziegler SE, a leading specialist in isotope-related components for nuclear medicine and radiation therapy, employs over 1,000 people. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Its shares are listed in the TecDAX index of Deutsche Börse.

The dividend increase signals the company's robust financial health and commitment to shareholder returns. This decision comes as Eckert & Ziegler continues to expand its role in the growing radiopharmaceutical sector, driven by increasing demand for targeted cancer therapies and diagnostic imaging agents.

Investors and analysts view the dividend hike as a positive indicator of the company's performance and future prospects. The approval of the dividend and other agenda items reflects strong shareholder confidence in the management's strategy. The company's focus on isotope technology positions it well for sustained growth in the healthcare industry.

For more information about the company and its services, visit Eckert & Ziegler's website.